Research Brief
CJC-1295: Research Applications
🔬 Adult Growth Hormone Deficiency (GHD) and Somatopause
CJC-1295 tem sido investigado(a) como um(a) alternative to daily rhGH injections for adults with GHD or age-related somatopause. Phase I data (Teichman et al., 2006) in adultos saudaveis (n=64) demonstrated que a single SC injection produziu dose-dependente GH aumenta (1.5 to 3-fold above baseline) lasting 9–11 days, with IGF-1 aumenta of 1.3 to 1.9-fold sustained for 9–11 days. [3] This durability profile positions CJC-1295 with DAC as um(a) potenteial uma vez por semana or biweekly pituitary secretagogue in GHD research models.
🔬 Body Composition Research
GH and IGF-1 regulate composicao corporal by stimulating lipolysis (fat breakdown) and protein synthesis (muscle anabolism). Estudos pre-clinicos in rodent models demonstrate que sustained GHRH receptor ativacao aumenta massa corporal magra and reduz tecido adiposo — effects mediated via IGF-1 signaling in muscle and fat tissue. [5] CJC-1295 with DAC produz continuous IGF-1 elevation que may amplify these composicao corporal effects comparado(a) a pulsatile delivery approaches.
🔬 Metabolic Research — HIV-Associated Lipodystrophy
Phase II trials in adults with HIV-associated lipodystrophy (fat redistribuicao syndrome) were iniciou by ConjuChem antes do(a) company's closure. This population was selected porque HIV antiretroviral therapy causes periferico(a) fat loss and central fat accumulation, with secondary GH axis supressao. CJC-1295 with DAC was hypothesized para restaurar GH/IGF-1 physiology and normalize fat distribuicao — a clinically meaningful endpoint in this population. [4] Development was discontinued sem publication of Phase II results.
🔬 Pediatric GHD (Preclinical Model)
Alba et al. (2006) studied GRF analogues in GH-deficient modelo de ratos, establishing the preclinical basis for dosing regimens translatable to pediatric GHD research. CJC-1295 with DAC showed dose-dependente normalization of growth parameters in hypophysectomized rodents — the standard in vivo model for GHD. [7]
🔬 Pituitary Biology and GH Axis Research
CJC-1295 with DAC serves como um(a) pharmacological tool compound for studying tonic vs. pulsatile GH axis estimulacao. Because it provides continuous, week-long GHRHr ativacao, it enables researchers to decouple o efeitos of GH pulse frequency from GH pulse amplitude — questions relevant to optimizing GH replacement therapy dosing regimens. [2]
| Research Domain | Evidence Level | Achado Principal |
|---|---|---|
| GHD/Somatopause | Phase I clinical | GH ↑ 1.5–3× for 9–11 days per injection |
| Body composition | Preclinical | Lean mass ↑, massa gorda ↓ in rodent models |
| HIV lipodystrophy | Phase II iniciou | Development discontinued; results unpublished |
| Pediatric GHD | Preclinical | Growth normalization in hypophysectomized rats |
| Pituitary biology | Preclinical/in vitro | Tool compound for tonic vs. pulsatile GH research |
Referencias
- Jetté L, et al. (2005). Human hormonio do crescimento-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor no(a) anterior pituitary in rats: identification of CJC-1295 como um(a) long-lasting GRF analog. Endocrinology, 146(7):3052–3058.
- Ionescu M, Frohman LA. (2006). Pulsatile secretion of hormonio do crescimento (GH) persists during continuous estimulacao by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab, 91(12):4792–4797.
- Teichman SL, et al. (2006). Prolonged estimulacao of hormonio do crescimento (GH) and insulin-like fator de crescimento I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in adultos saudaveis. J Clin Endocrinol Metab, 91(3):799–805.
- Alba M, et al. (2006). Once-monthly administration of CJC-1295, a long-acting hormonio do crescimento-releasing hormone (GHRH) analog, normalizes growth no(a) GHRH-deficient dwarf rat. Am J Physiol Endocrinol Metab, 291(6):E1290–E1294.
- Walker RF. (2006). Sermorelin: a better approach to management of adult-onset hormonio do crescimento insufficiency? Clin Interv Aging, 1(4):307–308.
- Ben-Shlomo A, et al. (2020). Growth hormone-releasing hormone (GHRH) e seu(sua) analogues: from bench to bedside. Neuroendocrinology, 110(3–4):192–199.
- Gahete MD, et al. (2009). In vivo e em vitro evidence para o(a) importance of hormonio do crescimento-releasing hormone no(a) regulacao of GH secretion. Mol Cell Endocrinol, 309(1–2):40–47.
- FDA. (2024). Substancia Farmaceutica a Granels Under Evaluation for Use in Compounding Under Section 503A: Categoria 2. Docket FDA-2013-N-1525. Federal Register, Dec 2024.
- WADA. (2024). List of Prohibited Substances and Methods. S2: Hormonios Peptidicos, Fatores de Crescimento, Substancias Relacionadas e Mimeticos. World Anti-Doping Agency.
- Frohman LA, Jansson JO. (1986). Growth hormone-releasing hormone. Endocr Rev, 7(3):223–253.
Perguntas de Pesquisa Relacionadas
APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.